You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Filter by group:
Filter by availability:
Displaying drugs 1426 - 1450 of 2005 in total
DrugBank ID Name Weight StructureCategoriesTherapeutic Indication
DB00831
117-89-5
Trifluoperazine407.496

C21H24F3N3S
ThumbPhenothiazines / Sulfur Compounds / Inorganic Chemicals / Heterocyclic Compounds, 3-Ring / Gastrointestinal Agents / Antiemetics / Antipsychotic Agents (First Generation [Typical]) / Cytochrome P-450 CYP1A2 Substrates / P-glycoprotein/ABCB1 Inhibitors / Dopamine Agents / Tranquilizing Agents / Central Nervous System Depressants / Psychotropic Drugs / Dopamine Antagonists / Alpha1 Antagonists / Combined Inhibitors of CYP3A4 and P-glycoprotein / Phenothiazines With Piperazine Structure / Antipsychotic Agents / Psycholeptics / Nervous System / Heterocyclic Compounds / Autonomic Agents / Neurotransmitter Agents / Molecular Mechanisms of Pharmacological Action / Organic Chemicals / Peripheral Nervous System Agents / Central Nervous System Agents / Therapeutic Uses / Physiological Effects of Drugs / Pharmacologic Actions / Chemical Actions and Uses / Phenothiazines with piperazine structureFor the treatment of anxiety disorders, depressive symptoms secondary to anxiety and agitation.
DB09031
58066-85-6
Miltefosine407.576

C21H46NO4P
ThumbAntiparasitic Agents / Antiprotozoals / Antineoplastic and Immunomodulating Agents / Anti-Infective Agents / Antifungal Agents / Antineoplastic Agents / Therapeutic Uses / Pharmacologic Actions / Chemical Actions and Uses / Other antineoplastic agentsFor the treatment of mucosal (caused by Leishmania braziliensis), cutaneous (caused by L. braziliensis, L. guyanensis, and L. panamensis), and visc...
DB00706
106133-20-4
Tamsulosin408.512

C20H28N2O5S
ThumbAdrenergic Agents / Adrenergic Antagonists / Adrenergic alpha-Antagonists / Adrenergic alpha-1 Receptor Antagonists / Alpha-Adrenoreceptor Antagonists / Drugs Used in Benign Prostatic Hypertrophy / Alpha1 Antagonists / Cytochrome P-450 CYP2D6 Substrates / Urological Agents / Genito Urinary System and Sex Hormones / Urologicals / Neurotransmitter Agents / Molecular Mechanisms of Pharmacological Action / Pharmacologic Actions / Chemical Actions and Uses / Therapeutic Uses / Physiological Effects of Drugs / Cytochrome P-450 CYP3A4 Substrates / Alpha-adrenoreceptor antagonists / Alpha-adrenoreceptor antagonists / Alpha-adrenoreceptor antagonistsUsed in the treatment of signs and symptoms of benign prostatic hyperplasia (reduction in urinary obstruction and relief of associated manifestatio...
DB02659
81-25-4
Cholic Acid408.5714

C24H40O5
ThumbCholic Acids / Cholanes / Bile Acids and Salts / Bile Acid Preparations / Bile Therapy / Bile and Liver Therapy / BSEP/ABCB11 Inhibitors / P-glycoprotein/ABCB1 Inducers / Alimentary Tract and Metabolism / OATP1B1/SLCO1B1 Substrates / Steroids / Combined Inducers of CYP3A4 and P-glycoprotein / Polycyclic Compounds / Bile acid preparationsOral cholic acid is indicated for: treatment of bile acid synthesis disorders due to single enzyme defects; and as adjunctive treatment of peroxiso...
DB06292
461432-26-8
Dapagliflozin408.873

C21H25ClO6
ThumbSodium-Glucose Transport Proteins, antagonists & inhibitors / Blood Glucose Lowering Drugs, Excl. Insulins / Drugs Used in Diabetes / Alimentary Tract and Metabolism / Cytochrome P-450 CYP2A6 Substrates / Hypotensive Agents / Blood Glucose Lowering Agents / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP1A2 Substrates / P-glycoprotein/ABCB1 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A4 Substrates / Other blood glucose lowering drugs, excl. insulins / Combinations of oral blood glucose lowering drugs / Combinations of oral blood glucose lowering drugsDapagliflozin is indicated for adjunct management of glycemic control in patients with type 2 diabetes mellitus, in combination with diet and exerc...
DB00381
88150-42-9
Amlodipine408.876

C20H25ClN2O5
ThumbDihydropyridines / Pyridines / Cardiovascular Agents / Membrane Transport Modulators / Vasodilator Agents / Calcium Channel Blockers / Antihypertensive Agents / ACE Inhibitors and Calcium Channel Blockers / Renin-Inhibitors / Dihydropyridine Derivatives / Selective Calcium Channel Blockers With Mainly Vascular Effects / Calcium Channel Blockers and Diuretics / Angiotensin II Antagonists and Calcium Channel Blockers / Cytochrome P-450 CYP2A6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors / P-glycoprotein/ABCB1 Inhibitors / Antianginal Agents / Hypotensive Agents / CYP3A4 Inhibitors (Weak) / Heterocyclic Compounds, 1-Ring / Lipid Modifying Agents / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP3A Inhibitors / Combined Inhibitors of CYP3A4 and P-glycoprotein / CYP2D6 Inhibitors (Weak) / Agents Acting on the Renin-Angiotensin System / Cardiovascular System / Heterocyclic Compounds / Molecular Mechanisms of Pharmacological Action / Cytochrome P-450 CYP3A4 Substrates / Therapeutic Uses / Pharmacologic Actions / Chemical Actions and Uses / HMG CoA reductase inhibitors, other combinations / ACE inhibitors and calcium channel blockers / Renin-inhibitors / ACE inhibitors, other combinations / HMG CoA reductase inhibitors, other combinations / Renin-inhibitors / ACE inhibitors and calcium channel blockers / ACE inhibitors and calcium channel blockers / Dihydropyridine derivatives / Calcium channel blockers and diuretics / HMG CoA reductase inhibitors, other combinations / Angiotensin II antagonists and calcium channel blockers / Angiotensin II antagonists and calcium channel blockers / Angiotensin II antagonists and calcium channel blockers / HMG CoA reductase inhibitors, other combinations / Angiotensin II antagonists and calcium channel blockers / Angiotensin II antagonists and calcium channel blockers / Angiotensin II antagonists, other combinations / Angiotensin II antagonists and calcium channel blockers / Angiotensin II antagonists, other combinationsFor the treatment of hypertension and chronic stable angina.
DB09237
103129-82-4
Levamlodipine408.88

C20H25ClN2O5
ThumbNot AnnotatedFor the treatment of hypertension.
DB00240
67452-97-5
Alclometasone408.916

C22H29ClO5
ThumbAdrenal Cortex Hormones / Glucocorticoids / Anti-Inflammatory Agents / Corticosteroids, Moderately Potent (Group II) / Corticosteroids, Plain / Corticosteroids, Dermatological Preparations / Ophthalmologicals / Sensory Organs / Cytochrome P-450 CYP3A Inducers / Combined Inducers of CYP3A4 and P-glycoprotein / Dermatologicals / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Physiological Effects of Drugs / Cytochrome P-450 CYP3A4 Substrates / Therapeutic Uses / Pharmacologic Actions / Chemical Actions and Uses / Corticosteroids, plainFor the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
DB00973
163222-33-1
Ezetimibe409.4252

C24H21F2NO3
ThumbAzetidines / Azetines / OATP1B1/SLCO1B1 Substrates / BCRP/ABCG2 Substrates / Heterocyclic Compounds, 1-Ring / Anticholesteremic Agents / Hypolipidemic Agents / Lipid Regulating Agents / Antimetabolites / Noxae / Toxic Actions / Lipid Modifying Agents, Plain / Lipid Modifying Agents / Cytochrome P-450 CYP3A Inhibitors / Combined Inhibitors of CYP3A4 and P-glycoprotein / Cardiovascular System / P-glycoprotein/ABCB1 Substrates / Heterocyclic Compounds / Molecular Mechanisms of Pharmacological Action / Therapeutic Uses / Pharmacologic Actions / Chemical Actions and Uses / HMG CoA reductase inhibitors in combination with other lipid modifying agents / HMG CoA reductase inhibitors in combination with other lipid modifying agents / Other lipid modifying agents / HMG CoA reductase inhibitors in combination with other lipid modifying agentsFor use as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, and Apo B in patients with primary (heterozygous familial and n...
DB01415
97519-39-6
Ceftibuten410.425

C15H14N4O6S2
ThumbAnti-Infective Agents / Therapeutic Uses / Pharmacologic Actions / Chemical Actions and Uses / Anti-Bacterial Agents / Third-Generation Cephalosporins / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Third-generation cephalosporinsUsed to treat acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis.
DB00223
2557-49-5
Diflorasone410.4515

C22H28F2O5
ThumbCorticosteroids, Potent (Group III) / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Adrenal Cortex Hormones / Glucocorticoids / Corticosteroids, Plain / Corticosteroids, Dermatological Preparations / Anti-Inflammatory Agents / Therapeutic Uses / Dermatologicals / Physiological Effects of Drugs / Pharmacologic Actions / Chemical Actions and Uses / Corticosteroids, potent (group III)For relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
DB00663
2135-17-3
Flumethasone410.458

C22H28F2O5
ThumbPregnadienetriols / Pregnadienes / Pregnanes / Steroids / Steroids, Fluorinated / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Adrenal Cortex Hormones / Glucocorticoids / Polycyclic Compounds / Anti-Inflammatory Agents / Therapeutic Uses / Physiological Effects of Drugs / Pharmacologic Actions / Chemical Actions and UsesFor the treatment of contact dermatitis, atopic dermatitis, exczema, psoriasis, diaper rash and other skin conditions
DB00734
106266-06-2
Risperidone410.4845

C23H27FN4O2
ThumbPyrimidinones / Pyrimidines / Heterocyclic Compounds, 1-Ring / Serotonin Agents / Dopamine Agents / Tranquilizing Agents / Central Nervous System Depressants / Psychotropic Drugs / Serotonin Antagonists / Dopamine Antagonists / Alpha2 Agonists / Alpha1 Antagonists / Antipsychotic Agents (Second Generation [Atypical]) / QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) / Hyperglycemia-Associated Agents / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP3A Inhibitors / Combined Inhibitors of CYP3A4 and P-glycoprotein / CYP2D6 Inhibitors (Weak) / Antipsychotic Agents / Psycholeptics / Nervous System / P-glycoprotein/ABCB1 Substrates / Heterocyclic Compounds / Neurotransmitter Agents / Molecular Mechanisms of Pharmacological Action / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A4 Substrates / Central Nervous System Agents / Therapeutic Uses / Physiological Effects of Drugs / Pharmacologic Actions / Chemical Actions and Uses / Other antipsychoticsFor the treatment of schizophrenia in adults and in adolescents, ages 13 to 17, and for the short-term treatment of manic or mixed episodes of bipo...
DB00838
4828-27-7
Clocortolone410.907

C22H28ClFO4
ThumbHormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Adrenal Cortex Hormones / Glucocorticoids / Corticosteroids, Moderately Potent (Group II) / Corticosteroids, Plain / Corticosteroids, Dermatological Preparations / Anti-Inflammatory Agents / Therapeutic Uses / Dermatologicals / Physiological Effects of Drugs / Pharmacologic Actions / Chemical Actions and Uses / Corticosteroids, moderately potent (group II)For short-term topical treatment of the inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the ...
DB01349
145733-36-4
Tasosartan411.4591

C23H21N7O
ThumbAngiotensin Receptor Antagonists / Angiotensin II Type 1 Receptor Blockers / Cardiovascular System / Agents Acting on the Renin-Angiotensin System / Angiotensin II Antagonists, Plain / Molecular Mechanisms of Pharmacological Action / Pharmacologic Actions / Chemical Actions and Uses / Cytochrome P-450 CYP3A4 Substrates / Angiotensin II antagonists, plainTasosartan is infrequently in the treatment of hypertension and heart failure.
DB01095
93957-54-1
Fluvastatin411.4659

C24H26FNO4
ThumbAntioxidants / Anticholesteremic Agents / Hypolipidemic Agents / Lipid Regulating Agents / Antimetabolites / Noxae / Toxic Actions / Enzyme Inhibitors / Hydroxymethylglutaryl-CoA Reductase Inhibitors / Lipid Modifying Agents, Plain / Lipid Modifying Agents / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Inducers / Combined Inducers of CYP3A4 and P-glycoprotein / Combined Inhibitors of CYP3A4 and P-glycoprotein / Cytochrome P-450 CYP2C9 Inhibitors (moderate) / CYP2D6 Inhibitors (Weak) / Cardiovascular System / Molecular Mechanisms of Pharmacological Action / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A4 Substrates / Therapeutic Uses / Pharmacologic Actions / Chemical Actions and Uses / HMG CoA reductase inhibitorsTo be used as an adjunct to dietary therapy to prevent cardiovascular events. May be used as secondary prevention in patients with coronary heart d...
DB09292
149709-62-6
Sacubitril411.498

C24H29NO5
ThumbAgents Acting on the Renin-Angiotensin System / Cardiovascular System / Angiotensin II antagonists, other combinationsUsed in combination with valsartan to reduce the risk of cardiovascular events in patients with chronic heart failure (NYHA Class II-IV) and reduce...
DB01063
2751-68-0
Acetophenazine411.56

C23H29N3O2S
ThumbPhenothiazines With Piperazine Structure / Antipsychotic Agents / Psycholeptics / Nervous System / Phenothiazines with piperazine structureFor the treatment of disorganized and psychotic thinking. Also used to help treat false perceptions (e.g. hallucinations or delusions.)
DB06702
286930-02-7
Fesoterodine411.5769

C26H37NO3
ThumbUrological Agents / Muscarinic Antagonists / Drugs for Urinary Frequency and Incontinence / Urologicals / P-glycoprotein/ABCB1 Substrates / Genito Urinary System and Sex Hormones / Cholinergic Agents / Neurotransmitter Agents / Molecular Mechanisms of Pharmacological Action / Cholinergic Antagonists / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A4 Substrates / Therapeutic Uses / Physiological Effects of Drugs / Pharmacologic Actions / Chemical Actions and Uses / Drugs for urinary frequency and incontinenceFor the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence).
DB00639
64872-76-0
Butoconazole411.776

C19H17Cl3N2S
ThumbAntifungal Agents / Imidazole Derivatives / Gynecological Antiinfectives and Antiseptics / Antifungal Agents (Vaginal) / Genito Urinary System and Sex Hormones / Pharmacologic Actions / Chemical Actions and Uses / Therapeutic Uses / Anti-Infective Agents / Imidazole derivativesFor the local treatment of vulvovaginal candidiasis (infections caused by Candida)
DB00332
22254-24-6
Ipratropium bromide412.361

C20H30BrNO3
ThumbAtropine Derivatives / Belladonna Alkaloids / Tropanes / Azabicyclo Compounds / Bicyclo Compounds, Heterocyclic / Heterocyclic Compounds, Bridged-Ring / Heterocyclic Compounds / Heterocyclic Compounds, 2-Ring / Bicyclo Compounds / Bridged Compounds / Aza Compounds / Alkaloids / Solanaceous Alkaloids / Anti-Asthmatic Agents / Respiratory System Agents / Autonomic Agents / Cholinergic Agents / Neurotransmitter Agents / Molecular Mechanisms of Pharmacological Action / Bronchodilator Agents / Cholinergic Antagonists / Drugs for Obstructive Airway Diseases / Respiratory System / Adrenergics, Inhalants / Nasal Preparations / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A4 Substrates / Polycyclic Compounds / Hydrocarbons, Cyclic / Hydrocarbons / Organic Chemicals / Peripheral Nervous System Agents / Therapeutic Uses / Physiological Effects of Drugs / Pharmacologic Actions / Chemical Actions and Uses / Other nasal preparations / Adrenergics in combination with anticholinergics / Adrenergics in combination with anticholinergicsFor maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.
DB00210
106685-40-9
Adapalene412.5201

C28H28O3
ThumbNaphthalenes / Polycyclic Hydrocarbons, Aromatic / Polycyclic Compounds / Hydrocarbons, Aromatic / Hydrocarbons, Cyclic / Hydrocarbons / Organic Chemicals / Analgesics, Non-Narcotic / Analgesics / Sensory System Agents / Peripheral Nervous System Agents / Physiological Effects of Drugs / Pharmacologic Actions / Chemical Actions and Uses / Central Nervous System Agents / Therapeutic Uses / Antirheumatic Agents / Anti-Inflammatory Agents / Anti-Inflammatory Agents, Non-Steroidal / Dermatologic Agents / Retinoids for Topical Use in Acne / Anti-Acne Preparations for Topical Use / Anti-Acne Preparations / Dermatologicals / Retinoids for topical use in acne / Retinoids for topical use in acneFor the topical treatment of comedo, papular and pustular acne (acne vulgaris) of the face, chest or back.
DB00587
128312-51-6
Cinalukast412.545

C23H28N2O3S
ThumbNot AvailableFor Protection against second- phase inflamation in exercise-induced bronchoconstriction and Asthma.
DB02300
112965-21-6
Calcipotriol412.6047

C27H40O3
ThumbAntineoplastic Agents / Therapeutic Uses / Dermatologic Agents / Antipsoriatics for Topical Use / Antipsoriatics / Dermatologicals / Pharmacologic Actions / Chemical Actions and Uses / Other antipsoriatics for topical use / Other antipsoriatics for topical useFor the treatment of moderate plaque psoriasis in adults.
DB06410
54573-75-0
Doxercalciferol412.6478

C28H44O2
ThumbMicronutrients / Growth Substances / Physiological Effects of Drugs / Pharmacologic Actions / Chemical Actions and Uses / Food / Food and Beverages / Diet, Food, and Nutrition / Physiological Phenomena / Vitamins / Bone Density Conservation Agents / Anti-Parathyroid Agents / Calcium Homeostasis / Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins / Other anti-parathyroid agentsDoxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as for...
Displaying drugs 1426 - 1450 of 2005 in total